Buscar
Mostrando ítems 1-10 de 3316
Recent treatment advances in HER2-positive metastatic breast cancer: a clinical approach
(2012-05)
The use of targeted therapy directed against HER2 is currently the standard of care in patients with metastatic HER2-positive breast cancer. The combination of trastuzumab with a taxane as first-line treatment in HER2-positive ...
Recent treatment advances in HER2-positive metastatic breast cancer: a clinical approach
(2012-05)
The use of targeted therapy directed against HER2 is currently the standard of care in patients with metastatic HER2-positive breast cancer. The combination of trastuzumab with a taxane as first-line treatment in HER2-positive ...
HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors
(Ivyspring Int Publ, 2017-01-01)
Persistent HPV infection alone is not sufficient for cervical cancer development, which requires additional molecular alterations for tumor progression and metastasis ultimately leading to a lethal disease. In this study, ...
Avaliação do HER2 em Câncer gástrico: correlação entre expressão proteica, amplificação gênica e características clinicopatológicas
(Universidade Federal de Minas GeraisUFMG, 2016-02-22)
Introduction: Gastric cancer is usually diagnosed in an advanced stage of disease and treatment options are sparse. Trastuzumab was recently approved for patients with HER2-positive gastric tumors. Although anti-HER2 ...
Neoadjuvant pertuzumab in non-metastatic HER2-positive breast tumors: Multicentric study in Peru (NeoHer)
(Spandidos Publications, 2022)
Several clinical trials have demonstrated the benefit of adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The ...
Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer
(Universidad de Murcia, 2017-07)
Fatty acid synthase (FASN) is a key lipogenic enzyme for de novo fatty acid biosynthesis and a druggable metabolic oncoprotein that is activated in most human cancers. We evaluated whether the HER2-driven lipogenic phenotype ...
Effects of lapatinib on her2-positive and her2-negative canine mammary carcinoma cells cultured in vitro
(2021-06-01)
HER2 is a prognostic and predictive marker widely used in breast cancer. Lapatinib is a tyrosine kinase inhibitor that works by blocking the phosphorylation of the receptor HER2. Its use is related to relatively good results ...
Expressão imunoistoquímica de HER2 em adenocarcinoma do estômago na região central do Rio Grande do Sul
(Universidade Federal de Santa MariaBRMedicinaUFSMPrograma de Pós-Graduação em Ciências da Saúde, 2013-07-30)
Introduction: Worldwide, Gastric Cancer (GC) is the fourth cancer in incidence and the second most common cause of cancer death. Because it is asymptomatic in the early stages, it is often diagnosed in advanced stages. ...
Peripheral position of CCND1 and HER-2/neu oncogenes within chromosome territories in esophageal and gastric cancers non-related to amplification and overexpression
(Sociedade Brasileira de Genética, 2014)
Positive HER-2 protein expression in circulating prostate cells and micro-metastasis, resistant to androgen blockage but not diethylstilbestrol
(Facultad de Ciencias, 2011)
Introduction : HER-2 expression in prostate cancer is associated with a worse prognosis and is suggested to play a role in androgen resistance. We present a study of HER-2 expression in circulating tumor cells and ...